HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
TCRT
Alaunos Therapeutics, Inc.
There isn't enough reported data to score TCRT yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
TCRT Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Unavailable |
TCRT's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
TCRT PE Valuation
TCRT has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
TCRT Forward outlook
There aren't enough analyst estimates for TCRT to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
TCRT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.90 | +$0.51 |
| Q1 2026 | -$2.12 | +$0.37 |
| Q4 2025 | -$2.20 | +$0.72 |
| Q3 2025 | -$2.26 | +$4.25 |
| Q2 2025 | -$2.41 | +$9.40 |
| Q1 2025 | -$2.49 | +$14.61 |
| Q4 2024 | -$2.92 | +$19.08 |
| Q3 2024 | -$6.51 | +$15.99 |
TCRT has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over TCRT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
TCRT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $3K | -25% |
| Q1 2025 | $2K | +100% |
| Q4 2024 | $4K | +300% |
| Q2 2024 | $4K | 0% |
| Q4 2023 | $1K | -91% |
| Q3 2022 | $2.9M | +631% |
TCRT's revenue has slid since its 2022 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -30233% | -11358 points |
| Q1 2025 | -54600% | +119600 points |
| Q4 2024 | -18875% | +776025 points |
| Q2 2024 | -29150% | +170400 points |
| Q1 2024 | -174200% | N/A |
| Q4 2023 | -794900% | -717436 points |
| Q2 2023 | -199550% | N/A |
| Q4 2022 | -77464% | N/A |
TCRT's operating margin was −30233% last quarter, up 143967 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
TCRT has the stronger cash trend. Its trailing FCF is up 93% versus its history, compared with HIMS at down 84%.
TCRT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$300K | +$401K |
| Q1 2026 | -$1M | -$259K |
| Q4 2025 | -$553K | +$39K |
| Q2 2025 | -$701K | +$980K |
| Q1 2025 | -$772K | +$1.1M |
| Q4 2024 | -$592K | +$6.8M |
| Q3 2024 | -$781K | +$5.6M |
| Q2 2024 | -$1.7M | +$5.5M |
TCRT has burned cash in almost every quarter: −$3M over the past year, against −$4M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over TCRT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
TCRT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +25% | +483K shares |
| 1 year | +45% | +755K shares |
| 3 years | +52% | +833K shares |
| 5 years | +70% | +1M shares |
| Available history | +114% | +1.3M shares |
TCRT has 2M diluted shares, up 45% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q4 2022 | — |
| Q4 2019 | $283,000 |
| Q3 2019 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
TCRT Net Leverage
TCRT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
TCRT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.5 | Neutral |
| Stochastic | 28.6 | Neutral |
TCRT's weekly RSI is 45 (neutral) and its Stochastic is 29 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
TCRT PE vs Healthcare Sector
| Metric | TCRT | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
TCRT has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
TCRT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.61 | 0.6% above |
| 20 week MA | $1.73 | 6.4% below |
| 50 week MA | $2.43 | 33% below |
| 100 week MA | $2.50 | 35% below |
| 200 week MA | $17.4 | 91% below |
TCRT has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over TCRT on returns for 2026, with the stronger performance.
TCRT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $772.5 | $432.0 | -44% |
| 2021 | $432.0 | $189.0 | -56% |
| 2022 | $189.0 | $88.2 | -53% |
| 2023 | $88.2 | $10.6 | -88% |
| 2024 | $10.6 | $1.84 | -83% |
| 2025 | $1.84 | $3.23 | +76% |
| 2026 YTD | $3.23 | $1.62 | -50% |
TCRT has finished lower in five of the last six years. It's down 50% so far in 2026.